Drug Trial Radar · NCT04152200
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Last checked: Nov 20, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jan 21, 2020
Primary completion
May 18, 2021
Study completion Jun 23, 2025
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
Conditions
- Primary Hyperoxaluria Type 1
- Primary Hyperoxaluria
Interventions
LumasiranDrug
Lumasiran will be administered by subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6Time frame: Baseline to Month 6
- Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6Time frame: Baseline to Month 6
Locations
14 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Garran, Australia
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Bron, France
Clinical Trial Site
Lyon, France
Clinical Trial Site
Haifa, Israel
Clinical Trial Site
Nahariya, Israel
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Irbid, Jordan
Clinical Trial Site
Beirut, Lebanon
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Yenimahalle, Turkey (Türkiye)
Clinical Trial Site
Dubai, United Arab Emirates
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.